Limits...
Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus

Time to 50% inhibition of thromboxane synthesis after ingestion of aspirin by chewing a tablet, swallowing a solution or swallowing a whole tablet [2].
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3298410&req=5

f2-can-6-245: Time to 50% inhibition of thromboxane synthesis after ingestion of aspirin by chewing a tablet, swallowing a solution or swallowing a whole tablet [2].

Mentions: The way a dose form is taken has a strong influence on its transit time from the mouth to the stomach – shorter when sitting upright and if the dose is swallowed with water – and may influence its therapeutic effect. For example, the rate of onset of effect of aspirin is more rapid if a tablet is chewed than if it is swallowed in solution or as a whole tablet [2]. In healthy volunteers, the mean time to 50 per cent inhibition of thromboxane synthesis was 5.0 minutes after chewing, 7.6 minutes after the solution and 12.0 minutes after a solid tablet (Figure 1[2]). Surprisingly, morbidities which affect posture, such as kyphosis, do not appear to affect transit time.


Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Time to 50% inhibition of thromboxane synthesis after ingestion of aspirin by chewing a tablet, swallowing a solution or swallowing a whole tablet [2].
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3298410&req=5

f2-can-6-245: Time to 50% inhibition of thromboxane synthesis after ingestion of aspirin by chewing a tablet, swallowing a solution or swallowing a whole tablet [2].
Mentions: The way a dose form is taken has a strong influence on its transit time from the mouth to the stomach – shorter when sitting upright and if the dose is swallowed with water – and may influence its therapeutic effect. For example, the rate of onset of effect of aspirin is more rapid if a tablet is chewed than if it is swallowed in solution or as a whole tablet [2]. In healthy volunteers, the mean time to 50 per cent inhibition of thromboxane synthesis was 5.0 minutes after chewing, 7.6 minutes after the solution and 12.0 minutes after a solid tablet (Figure 1[2]). Surprisingly, morbidities which affect posture, such as kyphosis, do not appear to affect transit time.

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus